A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2021-01-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with
Everolimus (Afinitor) on progression-free survival (PFS) and overall survival (OS) in
subjects with advanced renal cell cancer that has progressed after prior VEGFR tyrosine
kinase inhibitor therapy.